Journal
IMMUNOLOGY
Volume 162, Issue 1, Pages 11-16Publisher
WILEY
DOI: 10.1111/imm.13255
Keywords
Candida albicans; candidalysin; gut barrier; IL-17; mucosal disease
Categories
Funding
- Wellcome Trust [214229 Z 18 Z]
- Biotechnology & Biological Sciences Research Council [BB/N014677/1]
- National Institutes of Health [R37-DE022550]
- King's Health Partners Challenge Fund [R170501]
- Rosetrees Trust [M680]
- NIH Research at Guys and St. Thomas's NHS Foundation Trust
- King's College London Biomedical Research Centre [IS-BRC-1215-20006]
- Wellcome Trust [214229/Z/18/Z] Funding Source: Wellcome Trust
- BBSRC [BB/N014677/1] Funding Source: UKRI
- MRC [MC_PC_16048] Funding Source: UKRI
Ask authors/readers for more resources
Advancements in mycology have highlighted the significant impact of fungal microbes on human health. Candida albicans, a common fungus, not only causes infections but is also associated with various inflammatory disorders, suggesting new avenues for research.
As our understanding of mycology progresses, the impact of fungal microbes on human health has become increasingly evident.Candida albicansis a common commensal fungus that gives rise to local and systemic infections, particularly in immunocompromised patients where it can result in mortality. However,C. albicanshas also been quietly linked with a variety of inflammatory disorders, to which it has traditionally been considered incidental; recent studies may now provide new aspects of these relationships for further consideration. This review provides a novel perspective on the impact ofC. albicansand its peptide toxin, candidalysin, on human health, exploring their contributions to pathology within a variety of diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available